The market is driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness
1h Free Analyst Time
Technavio has been monitoring dementia and movement disorder treatment market is poised to grow by $7.14 billion during 2022-2026, accelerating at a CAGR of 6.95% during the forecast period.Speak directly to the analyst to clarify any post sales queries you may have.
This report on the dementia and movement disorder treatment market provides a holistic analysis, of market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis of the current global market scenario, the latest trends and drivers, and the overall market environment.
The market is driven by the growing geriatric population, the rising prevalence of target diseases, and the emergence of strategies to increase public awareness.
Dementia and movement disorder treatment market analysis include class segment and geographic landscape.
The dementia and movement disorder treatment market is segmented as below:
By Drug Class
- MAO inhibitors
- Acetylcholinesterase inhibitors
- Glutamate inhibitors
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. This report covers the following areas:
- Dementia and movement disorder treatment market sizing
- Dementia and movement disorder treatment market forecast
- Dementia and movement disorder treatment market industry analysis
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The analyst presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The analyst's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Drug Class
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The analyst recognizes the following companies as the key players in global dementia and movement disorder treatment market: AbbVie Inc., Acorda Therapeutics Inc., Amneal Pharmaceuticals Inc., Bausch Health Companies Inc., Biogen Inc., Eisai Co. Ltd., GlaxoSmithKline Plc, H Lundbeck AS, Johnson and Johnson, Kyowa Kirin Co. Ltd., Lannett Co. Inc., Merck and Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Organon and Co., Orion Pharma Ltd., Otsuka Holdings Co. Ltd., Supernus Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., UCB SA, and Vertical Pharmaceuticals LLC.Commenting on the report, an analyst said: ''The latest trend gaining momentum in the market is the emergence of biomarkers.''
According to the report, one of the major drivers for this market is the growing geriatric population.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie Inc.
- Acorda Therapeutics Inc.
- Amneal Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Biogen Inc.
- Eisai Co. Ltd.
- GlaxoSmithKline PLC
- H Lundbeck AS
- Johnson and Johnson
- Kyowa Kirin Co. Ltd.
- Lannett Co. Inc.
- Merck and Co. Inc.
- Neurocrine Biosciences Inc.
- Novartis AG
- Organon and Co.
- Orion Pharma Ltd.
- Otsuka Holdings Co. Ltd.
- Supernus Pharmaceuticals Inc.
- Teva Pharmaceutical Industries Ltd.
- UCB SA
- Vertical Pharmaceuticals LLC
